Lorea Valcarcel

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5893856/lorea-valcarcel-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15 626 11 18 g-index

18 860 14 4.04 ext. papers ext. citations avg, IF L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 15 | Crosstalk between mechanotransduction and metabolism. <i>Nature Reviews Molecular Cell Biology</i> , 2021 , 22, 22-38 | 48.7 | 69 |
| 14 | Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. <i>Journal of Experimental Medicine</i> , 2020 , 217, | 16.6 | 7 |
| 13 | Targeting PML in triple negative breast cancer elicits growth suppression and senescence. <i>Cell Death and Differentiation</i> , 2020 , 27, 1186-1199 | 12.7 | 10 |
| 12 | PGC1ISuppresses Prostate Cancer Cell Invasion through ERRITranscriptional Control. <i>Cancer Research</i> , 2019 , 79, 6153-6165 | 10.1 | 21 |
| 11 | PPARIElicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. <i>Cancer Research</i> , 2018 , 78, 399-409 | 10.1 | 15 |
| 10 | Low-dose statin treatment increases prostate cancer aggressiveness. <i>Oncotarget</i> , 2018 , 9, 1494-1504 | 3.3 | 9 |
| 9 | Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer. <i>Cell Death and Disease</i> , 2018 , 9, 1041 | 9.8 | 6 |
| 8 | Mitochondrial Metabolism: Yin and Yang for Tumor Progression. <i>Trends in Endocrinology and Metabolism</i> , 2017 , 28, 748-757 | 8.8 | 41 |
| 7 | mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017 , 547, 109-113 | 50.4 | 92 |
| 6 | Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer. <i>Oncotarget</i> , 2016 , 7, 6835-46 | 3.3 | 48 |
| 5 | Stratification and therapeutic potential of PML in metastatic breast cancer. <i>Nature Communications</i> , 2016 , 7, 12595 | 17.4 | 26 |
| 4 | The metabolic co-regulator PGC1I3 uppresses prostate cancer metastasis. <i>Nature Cell Biology</i> , 2016 , 18, 645-656 | 23.4 | 140 |
| 3 | Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015 , 308, E756-69 | 6 | 99 |
| 2 | Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. <i>Methods</i> , 2015 , 77-78, 25-30 | 4.6 | 16 |
| 1 | Altered circadian rhythm and metabolic gene profile in rats subjected to advanced light phase shifts. <i>PLoS ONE</i> , 2015 , 10, e0122570 | 3.7 | 24 |